Aphranel Recognized as a Leader in China's Beauty Industry by Forbes

Aphranel's Recognition in Forbes China Beauty 100

Aphranel, a pioneering brand in regenerative medical aesthetics, has been recognized in the prestigious Forbes China Beauty 100 list. This honor, awarded by Forbes China, highlights brands making significant strides in the beauty and aesthetics sector, showcasing their innovation and potential for growth.

This recognition is a testament to Aphranel's commitment to developing effective products and standards within the industry. The Forbes China Beauty 100 specifically acknowledges brands that demonstrate market performance, innovation, influence, and long-term growth potential in China’s dynamic beauty industry.

A Commitment to Long-Term Product Development

Aphranel, as a brand specializing in regenerative materials like Calcium Hydroxyapatite (CaHA), has adopted a long-term approach towards product development. This strategy emphasizes scientific research and clinical validation, ensuring their products meet high safety standards and effectiveness.

Its flagship product, the Aphranel CaHA injectable filler, features a unique structural system made up of 30% CaHA microspheres and 70% CMC support gel. This composition not only offers immediate structural support but also encourages collagen regeneration over time. The product incorporates patented ACD-MT™ microsphere technology and CMC PCD-ETT™ gel technology, ensuring optimal performance.

These microspheres, measuring approximately 30-35 μm with a special raspberry-shaped surface, enhance cellular adhesion and tissue integration. With a G' value around 5,500 Pa, the filler is engineered to provide stable support during injection. As the material gradually degrades, calcium ions released during the process contribute to tissue metabolism, leading to natural and gradual aesthetic improvements.

A Philosophical Approach: The Poetics of Time

Beyond product innovation, Aphranel has adopted a brand philosophy called “Aphranel Poetics of Time.” This philosophy emphasizes that aesthetic treatments should align with natural biological processes, promoting gradual and sustainable results instead of hasty transformations.

In line with this concept, Aphranel invests in physician training programs. These initiatives include academic exchange programs that focus on anatomical research and clinical support through imaging techniques, assisting physicians in assessing injection layers and understanding long-term outcomes.

Industry observers note that as China’s medical aesthetics sector becomes increasingly regulated and standardized, brands focusing on compliance, long-term clinical data accumulation, and professional training are gaining more recognition.

Future Directions

With this recognition from Forbes, Aphranel plans to amplify its investments in material research, clinical collaborations, and physician education. The goal is to strengthen the link between scientific innovation and clinical practice, enhancing trust among medical practitioners and patients alike.

Aphranel’s commitment to advancing the medical aesthetics field in China not only reflects its innovative spirit but also highlights the brand's dedication to longevity, safety, and efficacy in its offerings, setting a benchmark in a rapidly evolving industry.